Aurora Cannabis launches its first CBD medical product in Uruguay

0

NASDAQ | TSX: ACB

Bidiol is the only fully produced full spectrum cannabis oil in the country

EDMONTON, AB, September 29, 2021 / PRNewswire / – Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company that defines the future of cannabinoids around the world, has launched Bidiol, the first medical cannabis oil Uruguay which is produced entirely in the country. CBD oil is available in 3% and 10% strengths and is available in 10ml and 30ml vials, available at drugstores across the country.

Aurora Cannabis Logo (CNW Group / Aurora Cannabis Inc.)

“The launch of Bidiol took two years and is an integral part of our renewed strategy in Uruguay,” noted Miguel Martin, CEO of Aurora Cannabis. “We have prioritized key international markets with the potential to significantly expand their patient base. Our efforts include working with governments and local partners to do what works best in each market. There is no one-size-fits-all strategy – our approach has to be smart and nationally relevant. “

Leader in the international cannabis market, Aurora has reoriented its strategy to Uruguay focus exclusively on medical cannabis, with the aim of making the country its continental center of production and distribution. Aurora’s operation at Uruguay includes one of the only GMP certified cannabis processing facilities in the country.

CBD oil is authorized by the Ministry of Public Health of Uruguay for the treatment of refractory epilepsy in children and adolescents.

Aurora continues to develop its line of CBD oil products by Uruguay, with the intention of expanding its portfolio in the coming months.

About Aurore:

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Based at Edmonton, Alberta, Aurora is a global cannabis pioneer dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora drift, San Rafael ’71, Special of the day, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Driven by science and innovation, and with a focus on high quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medicine, performance, wellness and adult recreation, wherever they are launched. Learn more about www.auroramj.com and follow us on Twitter and LinkedIn.

Aurora’s common shares trade on the TSX and NASDAQ under the symbol “ACB” and are included in the S & P / TSX Composite Index.

Forward-looking information

This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “plan”, “intend”, “believe”, “anticipate”, “estimate”, “May”, “may”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements contained in this press release include statements regarding the launch of new products and the availability of products in pharmacies of Uruguay. These forward-looking statements are only predictions. Various assumptions have been used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made. made, such as current and future market conditions, the ability to keep SG&A Fees in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management considers relevant and reasonable in the circumstances that could cause events, results, level of activity, performance, actual prospects, opportunities or achievements differ materially from those projected in the forward-looking statements, including risks associated with: entering the U.S. market, the ability to realize the expected benefits associated with the Reliva acquisition, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, required commodity price changes, competition, pandemic effects and responses COVID-19 and other risks, uncertainties and factors set out under “Risk Factors” in the Annual Information Form of the Company dated September 27, 2021 (the “Annual Information Form”) and filed with the Canadian Securities Administrators, available on the Company’s Issuer Profile on SEDAR at www.sedar.com and filed with and available on the Company’s website. the SEC at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the Annual Information Form is not exhaustive and that other factors could also adversely affect its results. Readers are urged to carefully consider risks, uncertainties and assumptions when evaluating forward-looking statements and are cautioned not to place undue reliance on such information. The Company has no obligation and expressly disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law on applicable securities.

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/aurora-cannabis-launches-its-first-medical-cbd-product-in-uruguay-301388208.html

SOURCE Aurora Cannabis Inc.



Source link

Leave A Reply

Your email address will not be published.